A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Phase 2 Terminated 76 enrolled Merck KGaA, Darmstadt, Germany Merck, S.L., Spain · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms of improved embryo competence which allows to transfer less embryos to avoid high grade multiple pregnancy without reducing the pregnancy rate.

Timeline

Start: 2008-11
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Luveris	Protein / enzyme biologic	150 iu	Subcutaneous
Background	Gonal-f	Protein / enzyme biologic	300 iu	Subcutaneous

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Summary

Timeline

Drugs

Indications